SCYNEXIS, Inc. (NASDAQ:SCYX) [Trend Analysis] climbed reacts as active mover, shares a gain 2.00% to traded at $4.58 and the percentage gap among open changing to regular change was -6.68%. Drug development firm, SCYNEXIS, Inc. (SCYX) released that complete results of its two recently completed Phase 2 studies as well as the closing of a $15 million term loan with Solar Capital Ltd. (SLRC). In the first study, treatment with oral SCY-078 in patients with vulvovaginal candidiasis (VVC), resulted in importantly better clinical cure rates and fewer recurrences of VVC at the four-month follow-up when compared to the standard of care (oral fluconazole).
In the second study, which evaluated oral SCY-078 as a step down therapy in patients with invasive candidiasis, oral SCY-078 achieved the target exposure for efficacy and was well-tolerated. The firm’s current ratio calculated as 11.70 for the most recent quarter. The firm past twelve months price to sales ratio was 344.23 and price to cash ratio remained 2.05. As far as the returns are concern, the return on equity was recorded as -75.10% and return on investment was -67.70% while its return on asset stayed at -64.20%. The firm has total debt to equity ratio measured as 0.00.
Yahoo! Inc. (NASDAQ:YHOO) [Trend Analysis] try to make new thrust in street and making different trends, stocks trading ended with 0.39% to $43.35. Yahoo! Inc.’s (YHOO) embattled chief executive officer, Marissa Mayer, who last month revealed a hack that exposed at least 500 million accounts, is facing a fresh round of questions about the firm’s privacy safeguards following a report that she let the U.S. government secretly scan hundreds of millions of user e-mails.
“Their brand equity is going from bad to worse,” stated Sameet Sinha, an analyst at B. Riley. It’s a sensitive time for Yahoo, which in July agreed to sell its web businesses to Verizon Communications Inc. for $4.8 billion following years of trying to jump-start sales growth. The share price of YHOO attracts active investors, as stock price of week volatility recorded 1.30%. The stock is going forward to its 52-week low with 65.77% and lagging behind from its 52-week high price with -3.50%.